Pernix Therapeutics Holdings, Inc
) recently announced that its subsidiary, Hawthorn
Pharmaceuticals, Inc., has received approval from the US Food and
Drug Administration (FDA) for VITUZ oral solution (hydrocodone
bitartrate and chlorpheniramine maleate).
The US regulatory body has cleared VITUZ for the relief of
cough and symptoms associated with upper respiratory allergies or
common cold in adults. The approval of VITUZ expands Pernix's
cough and cold product line. The company plans to launch VITUZ in
We remind investors that on Jan 2, 2013 Pernix Therapeutics
completed the acquisition of Hawthorn Pharma. The erstwhile
Hawthorn Pharma offered branded pharmaceutical products for
allergy, respiratory, iron deficiency, nephrology and pain
We note that Pernix also acquired Cypress Pharmaceuticals, Inc
along with Hawthorn Pharma in Jan 2013. The erstwhile Cypress
Pharma offered generic drugs targeting the fields of cough and
cold, nutritional supplements, analgesics, urinary tract, women's
health, pre-natal vitamins and dental health.
Concurrent with the FDA approval for VITUZ, Pernix also
announced that the FDA has granted final approval to its
subsidiary, Cypress Pharmaceuticals, Inc., for an abbreviated new
drug application (ANDA) for mefenamic acid capsules USP, 250
Mefenamic acid capsules are a generic version of Shinonogi's
Ponstel and are primarily indicated for the relief of
mild-to-moderate pain in patients aged 14 years and above. The
drug is also approved for treating primary dysmenorrhea. Pernix
expects to launch the drug in the second quarter of 2013.
Pernix Therapeutics currently carries a Zacks Rank #2 (Buy).
Other pharma stocks, which also appear to be attractive, include
). All 3 stocks carry a Zacks Rank #2.
AVANIR PHARM (AVNR): Free Stock Analysis
FURIEX PHARMACT (FURX): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
PERNIX THERAPTC (PTX): Free Stock Analysis
To read this article on Zacks.com click here.